Palvella Therapeutics (PVLA) Operating Income (2016 - 2024)
Historic Operating Income for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$4.4 million.
- Palvella Therapeutics' Operating Income fell 13261.62% to -$4.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$14.1 million, marking a year-over-year decrease of 1875.47%. This contributed to the annual value of -$14.1 million for FY2024, which is 1875.47% down from last year.
- Palvella Therapeutics' Operating Income amounted to -$4.4 million in Q4 2024, which was down 13261.62% from -$5.1 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Operating Income ranged from a high of $13.4 million in Q4 2023 and a low of -$19.0 million during Q3 2021
- Moreover, its 5-year median value for Operating Income was -$9.2 million (2021), whereas its average is -$7.8 million.
- In the last 5 years, Palvella Therapeutics' Operating Income plummeted by 83315.79% in 2020 and then surged by 21620.8% in 2023.
- Over the past 5 years, Palvella Therapeutics' Operating Income (Quarter) stood at -$12.4 million in 2020, then grew by 11.38% to -$11.0 million in 2021, then fell by 4.73% to -$11.5 million in 2022, then skyrocketed by 216.21% to $13.4 million in 2023, then plummeted by 132.62% to -$4.4 million in 2024.
- Its Operating Income stands at -$4.4 million for Q4 2024, versus -$5.1 million for Q3 2024 and -$2.9 million for Q2 2024.